Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin
Launched by ALVOGEN KOREA · Mar 4, 2014
Trial Information
Current as of October 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy male volunteers af aged between 20 years to 45 years
- • Have a weight above 55kg and Ideal body weight (IBW) between -20% and +20% inclusive
- • Eligible subjects with acceptable medical history and physical examination
- Exclusion Criteria:
- • - Have a known hypersensitivity or history of clinically significant hypersensitivity to drugs including the same class drugs with candesartan or rosuvastatin, or other drugs
About Alvogen Korea
Alvogen Korea is a leading pharmaceutical company dedicated to the development, manufacturing, and commercialization of high-quality generic and specialty medications. With a strong emphasis on innovation and patient-centric solutions, Alvogen Korea leverages advanced technologies and robust research capabilities to deliver a diverse portfolio of therapeutic options across various medical fields. The company is committed to enhancing healthcare access through cost-effective products while ensuring compliance with stringent regulatory standards. Alvogen Korea actively collaborates with healthcare professionals and stakeholders to drive clinical research initiatives and contribute to the advancement of global health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jung Gu, Daejeon, Korea, Republic Of
Patients applied
Trial Officials
JangHee Hong, PhD.
Principal Investigator
Chungnam National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials